Your search for "SIGY" returned the following results.
Filter Results:
News Articles

Sigyn Therapeutics Inc. (SIGYD) Advancing Novel Therapeutic Technologies to Enhance the Benefit of Cancer Therapies, Treat Pathogen-Associated Conditions Beyond the Reach of Drugs

February 21, 2024

Sigyn Therapeutics (OTCQB: SIGYD, SIGY), a development-stage medical technology company creates therapeutic candidates with two prerequisites in mind: 1) they must offer to overcome a clearly defined limitation in global health, and 2) their successful clinical advancement would provide a potential competitive advantage within an established therapeutic industry segment. The company’s therapeutic candidates include: Sigyn […]


InvestorNewsBreaks – Sigyn Therapeutics Inc. (SIGY, SIGYD) Announces Implementation of a 1-for-40 Reverse Split

February 2, 2024

Sigyn Therapeutics (OTCQB: SIGY, SIGYD), a development-stage medical technology company, announced the completion of a 1-for-40 reverse split of its common stock. According to the announcement, the reverse split was implemented on Jan. 31, 2024. “As a result of the split, the company’s common stock will trade under the ticker symbol SIGYD for 20 business […]


InvestorNewsBreaks – Why Sigyn Therapeutics Inc. (SIGY) Is ‘One to Watch’

January 24, 2024

Sigyn Therapeutics (OTCQB: SIGY, SIGYD) is a development-stage medical technology company whose therapeutic candidates include Sigyn Therapy(TM), the ImmunePrep(TM) platform, ChemoPrep(TM), and ChemoPure(TM). “The company is advancing Sigyn Therapy to treat pathogen-associated inflammatory disorders that are not addressed with FDA-approved drugs. Candidate treatment indications include community-acquired pneumonia, drug-resistant virus and bacterial infections, endotoxemia, and sepsis, […]

News Articles

Sigyn Therapeutics Inc. (SIGY) Is ‘One to Watch’

January 8, 2024

Sigyn Therapeutics (OTCQB: SIGY, SIGYD) is a development-stage medical technology company headquartered in San Diego, California. The company’s therapeutic candidates include Sigyn Therapy(TM) to address pathogen-associated inflammatory disorders, the ImmunePrep(TM) platform to enhance the performance of immunotherapeutic antibodies, ChemoPrep(TM) to improve the delivery of cancer chemotherapy and ChemoPure(TM) to reduce the toxicity of chemotherapy. Sigyn […]


InvestorNewsBreaks – Sigyn Therapeutics Inc. (SIGY) CEO Releases Shareholder Letter Outlining Opportunities, Challenges, Processes

January 4, 2024

Sigyn Therapeutics (OTCQB: SIGY, SIGYD), a development-stage medical technology company, has released a shareholder letter from chair and CEO Jim Joyce. In the letter, whose objective is to help shareholders better understand SIGY opportunities, challenges and decision-making processes, Joyce reiterates the company’s long-term objective of building an enduring organization whose therapies save lives. The letter […]

News Articles

SideChannel Inc. (SDCH) Ability To Make Powerful Cybersecurity Accessible For Small and Mid-sized Companies Results In 64% to 71% Year-Over-Year Revenue Increase

December 8, 2022

With a mission to make cybersecurity simple and accessible, SideChannel’s (OTCQB: SDCH) belief is that small and mid-sized organizations deserve the expertise of an experienced CISO (Chief Information Security Officer), just as much as a larger enterprise but at a more reasonable cost. The company is helping organizations all over the world improve their cybersecurity […]

News Articles

Q4 Investor Summit Small Cap & Micro Cap Conference To Offer Opportunity to Meet with C-level Management of 90+ Companies

November 15, 2021

 Virtual:  November 16 – 17, 2021 Small and Micro-cap investors are invited to attend the Q4 Investor Summit being held on November 16-17, 2021. The event is organized by the Investor Summit Group, recognised as a highly reputed brand for hosting North America’s largest independent investor conferences.  Over 90 presenting companies from a wide spectrum […]

No ResultsNo content matches your search/filter.




Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).